Latest News & Announcements
The List: Top 100 Innovators 2024
A Brisbane-led project using 1918 Spanish flu tissue is now advancing global cancer treatment research.
De Motu Cordis (DMC) Applauds ARS Pharma’s FDA Approval of Neffy®, Expanding Patient Options to Needle-Free Epinephrine Delivery and Inspiring Confidence in Our Own Development Efforts.
De Motu Cordis (DMC) is pleased to acknowledge and enthusiastically commends the recent U.S. FDA approval of ARS Pharma’s Neffy®, the first-ever needle-free intranasal epinephrine delivery device for the treatment of anaphylaxis.
De Motu Cordis (DMC) announces plans for the next stage of development for DMC-IH1, an inhaled epinephrine drug device combination product
De Motu Cordis (DMC) today announced plans for the next stage of development with its Contract Development and Manufacturing Organization (CDMO) partner, Catalent, at Catalent’s Boston, Morrisville and San Diego sites.
Forbes magazine features DMC founder – how Professor John Fraser aims to ensure that through innovation, patients thrive, not just survive
Professor John Fraser’s Belfast born grandmother was one of the first women to qualify in Northern Ireland as a doctor. It was the 1900s, and she was there to rebel, to change outcomes and to prove that women could do just as well as men.
BiVacor Receives Grant to Support Clinical Trials for Total Artificial Heart
BiVACOR – a clinical-stage medical device company with world headquarters based in California and International Office based in Brisbane – is awarded US$13 million from the Australian Government’s Medical Research Future Fund grant through the Artificial Heart Frontiers Program.
DMC Director, Doctor Glen Richards, a 2023 UQ Alumni Award winner!
Dr Glen Richards is a business leader, entrepreneur and veterinarian.
BEDA MedTech official ambassador
Great to have DMC Founder performing a pivotal role for QLD MedTech – building a bridge to the global stage.
De Motu Cordis (DMC) welcomed Queensland Treasurer and Minister for Trade and Investment Honourable Cameron Dick MP
On April 4, 2023, De Motu Cordis (DMC) welcomed Queensland Treasurer and Minister for Trade and Investment Honourable Cameron Dick MP to our Brisbane premises.
Press Release 27 February 2023
De Motu Cordis reports progress on the development of its dry powder inhaler (DPI) containing epinephrine (adrenaline) for inhaled anaphylaxis treatment.
DMC Founder Professor John Fraser a co-lead on the Living Heart Project giving the gift of life
Professor John Fraser and his team have been working on the Living Heart Project for over five years in developing a technology to keep hearts viable for longer, giving a much needed boost to heart transplant recipients.
JPM Week – San Francisco
In the first global sharing of its innovative solution for anaphylaxis treatment, De Motu Cordis (DMC) reports progress on its dry powder inhaler (DPI) containing epinephrine (adrenaline) for inhaled anaphylaxis treatment.
DMC Founder, Professor John Fraser, a LSQ GENE Awards winner!
Congratulations to our Company Founder, Professor John Fraser, who on Friday November 18, 2022, was the recipient of the Life Sciences Queensland (LSQ) McCullough Robertson Industry Excellence Award.
